SN. Stock Overview
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide.
No risks detected for SN. from our risk checks.
Smith & Nephew Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£11.65|
|52 Week High||UK£16.02|
|52 Week Low||UK£11.08|
|1 Month Change||-10.15%|
|3 Month Change||-5.98%|
|1 Year Change||-25.28%|
|3 Year Change||-32.69%|
|5 Year Change||-10.90%|
|Change since IPO||621.80%|
Recent News & Updates
Smith & Nephew plc's (LON:SN.) Intrinsic Value Is Potentially 58% Above Its Share Price
How far off is Smith & Nephew plc ( LON:SN. ) from its intrinsic value? Using the most recent financial data, we'll...
|SN.||GB Medical Equipment||GB Market|
Return vs Industry: SN. underperformed the UK Medical Equipment industry which returned -23% over the past year.
Return vs Market: SN. underperformed the UK Market which returned -8.6% over the past year.
|SN. Average Weekly Movement||3.8%|
|Medical Equipment Industry Average Movement||5.5%|
|Market Average Movement||5.5%|
|10% most volatile stocks in GB Market||10.8%|
|10% least volatile stocks in GB Market||2.8%|
Stable Share Price: SN. is less volatile than 75% of UK stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: SN.'s weekly volatility (4%) has been stable over the past year.
About the Company
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems.
Smith & Nephew Fundamentals Summary
|SN. fundamental statistics|
Is SN. overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SN. income statement (TTM)|
|Cost of Revenue||US$1.51b|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Jul 28, 2022
|Earnings per share (EPS)||0.60|
|Net Profit Margin||10.05%|
How did SN. perform over the long term?See historical performance and comparison
2.6%Current Dividend Yield
Is SN. undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SN.?
Other financial metrics that can be useful for relative valuation.
|What is SN.'s n/a Ratio?|
Price to Earnings Ratio vs Peers
How does SN.'s PE Ratio compare to its peers?
|SN. PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
CTEC ConvaTec Group
EKF EKF Diagnostics Holdings
MDC Mediclinic International
IHC Inspiration Healthcare Group
SN. Smith & Nephew
Price-To-Earnings vs Peers: SN. is good value based on its Price-To-Earnings Ratio (23.8x) compared to the peer average (24.6x).
Price to Earnings Ratio vs Industry
How does SN.'s PE Ratio compare vs other companies in the European Medical Equipment Industry?
Price-To-Earnings vs Industry: SN. is expensive based on its Price-To-Earnings Ratio (23.8x) compared to the UK Medical Equipment industry average (21.1x)
Price to Earnings Ratio vs Fair Ratio
What is SN.'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||23.6x|
|Fair PE Ratio||39.1x|
Price-To-Earnings vs Fair Ratio: SN. is good value based on its Price-To-Earnings Ratio (23.8x) compared to the estimated Fair Price-To-Earnings Ratio (39.2x).
Share Price vs Fair Value
What is the Fair Price of SN. when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SN. (£11.65) is trading below our estimate of fair value (£18.4)
Significantly Below Fair Value: SN. is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: SN. is poor value based on its PEG Ratio (1.7x)
Discover undervalued companies
How is Smith & Nephew forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?
Future Growth Score3/6
Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SN.'s forecast earnings growth (14.3% per year) is above the savings rate (0.9%).
Earnings vs Market: SN.'s earnings (14.3% per year) are forecast to grow faster than the UK market (11% per year).
High Growth Earnings: SN.'s earnings are forecast to grow, but not significantly.
Revenue vs Market: SN.'s revenue (4.5% per year) is forecast to grow faster than the UK market (4.1% per year).
High Growth Revenue: SN.'s revenue (4.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SN.'s Return on Equity is forecast to be low in 3 years time (15.5%).
Discover growth companies
How has Smith & Nephew performed over the past 5 years?
Past Performance Score3/6
Past Performance Score 3/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SN. has high quality earnings.
Growing Profit Margin: SN.'s current net profit margins (10.1%) are higher than last year (9.8%).
Past Earnings Growth Analysis
Earnings Trend: SN.'s earnings have declined by 12.6% per year over the past 5 years.
Accelerating Growth: SN.'s earnings growth over the past year (17%) exceeds its 5-year average (-12.6% per year).
Earnings vs Industry: SN. earnings growth over the past year (17%) underperformed the Medical Equipment industry 22.3%.
Return on Equity
High ROE: SN.'s Return on Equity (9.4%) is considered low.
Discover strong past performing companies
How is Smith & Nephew's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: SN.'s short term assets ($4.4B) exceed its short term liabilities ($2.1B).
Long Term Liabilities: SN.'s short term assets ($4.4B) exceed its long term liabilities ($3.2B).
Debt to Equity History and Analysis
Debt Level: SN.'s net debt to equity ratio (33.3%) is considered satisfactory.
Reducing Debt: SN.'s debt to equity ratio has increased from 41.5% to 56.4% over the past 5 years.
Debt Coverage: SN.'s debt is well covered by operating cash flow (27.9%).
Interest Coverage: SN.'s interest payments on its debt are well covered by EBIT (9.6x coverage).
Discover healthy companies
What is Smith & Nephew current dividend yield, its reliability and sustainability?
Dividend Score 5/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: SN.'s dividend (2.62%) is higher than the bottom 25% of dividend payers in the UK market (1.88%).
High Dividend: SN.'s dividend (2.62%) is low compared to the top 25% of dividend payers in the UK market (5.18%).
Stability and Growth of Payments
Stable Dividend: SN.'s dividends per share have been stable in the past 10 years.
Growing Dividend: SN.'s dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonable payout ratio (62.8%), SN.'s dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonable cash payout ratio (69.7%), SN.'s dividend payments are covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Deepak Nath (48 yo)
Dr. Deepak S. Nath, Ph.D. served as Head of Diagnostics at Siemens Healthineers AG since 2021 until 2022 and served as its President of Laboratory Diagnostics since 2018 until 2021 where he led a major pro...
Experienced Management: SN.'s management team is considered experienced (3.2 years average tenure).
Experienced Board: SN.'s board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Smith & Nephew plc's employee growth, exchange listings and data sources
- Name: Smith & Nephew plc
- Ticker: SN.
- Exchange: LSE
- Founded: 1856
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: UK£10.150b
- Shares outstanding: 871.26m
- Website: https://www.smith-nephew.com
Number of Employees
- Smith & Nephew plc
- Building 5
- Croxley Park
- WD18 8YE
- United Kingdom
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/28 00:00|
|End of Day Share Price||2022/06/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.